IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval
NXC-201, a novel CAR T therapy for AL amyloidosis, shows high complete response rates, rapid and durable efficacy, and a favorable safety profile. Regulatory designations and a strong cash position support accelerated approval and commercial launch, with a Phase III trial underway in the frontline…